DULERA (MOMETASONE FUROATE/FORMOTEROL FUMARATE)
- Maintenance therapy for asthma
100 mcg-5 mcg/actuation HFA aerosol inhaler
- Inhale 2 puffs by inhalation route 2 times per day in the morning andevening
200 mcg-5 mcg/actuation HFA aerosol inhaler
- Inhale 2 puffs by inhalation route 2 times per day in the morning andevening
Maintenance therapy for asthma
- Inhale 2 puffs by inhalation route 2 times per day in the morning andevening
- Inhale 2 puffs by inhalation route every 12 hours
- natalizumab
- Tysabri
Contraindicated
- boceprevir
- bromocriptine
- cabergoline
- Cafergot
- Compound 347
- Cycloset
- D.h.e.45
- dihydroergotamine
- elvitegr-cobicist-emtric-tenof
- enflurane
- ergoloid
- Ergomar
- ergotamine tartrate
- ergotamine-caffeine
- Forane
- Incivek
- isoflurane
- Kaletra
- Korlym
- lopinavir-ritonavir
- methylergonovine
- Mifeprex
- mifepristone
- Migergot
- Migranal
- Norvir
- Norvir Soft Gelatin
- Parlodel
- ritonavir
- sevoflurane
- Sojourn
- Stribild
- telaprevir
- Terrell
- Ultane
- Victrelis
Severe
Moderate
- amoxicil-clarithromy-lansopraz
- Avelox
- Avelox Abc Pack
- Avelox In Nacl (iso-osmotic)
- Biaxin
- Biaxin Xl
- Biaxin Xl Pak
- Cipro
- Cipro In D5W
- Cipro Xr
- ciprofloxacin
- ciprofloxacin (mixture)
- ciprofloxacin in D5W
- clarithromycin
- Erythrocin
- erythromycin
- erythromycin-sulfisoxazole
- itraconazole
- ketoconazole
- Levaquin
- Levaquin In 5 % Dextrose
- levofloxacin
- levofloxacin in D5W
- moxifloxacin
- moxifloxacin in NaCl (iso-osm)
- norfloxacin
- Noroxin
- ofloxacin
- Omeclamox-pak
- omeprazole-clarith-amoxicillin
- Onmel
- Prevpac
- Sporanox
- Sporanox Pulsepak
- Acutely deteriorating asthma
Contraindicated
- Congenital long QT syndrome
- Fungal infection
- Hypokalemia
- Ocular herpes simplex
- Ocular hypertension
- Osteoporosis
- Parasitic infection
- Prolonged QT interval
Severe
Moderate
- Active tuberculosis
- Cardiac arrhythmia
- Cataracts
- Chickenpox
- Chronic myocardial ischemia
- Diabetes mellitus
- Disease of liver
- Glaucoma
- Hypertension
- Hypothalamic-pituitary insufficiency
- Immunosuppression
- Measles
- Osteopenia
- Seizure disorder
- Thyrotoxicosis
DULERA (MOMETASONE FUROATE/FORMOTEROL FUMARATE)
- Maintenance therapy for asthma
- None
- Allergic rhinitis
- Back pain
- Diarrhea
- Dizziness
- Dysmenorrhea
- Dyspepsia
- Headache disorder
- Insomnia
- Musculoskeletal pain
- Nausea
- Oral candidiasis
- Pharyngitis
- Sinusitis
- Upper respiratory infection
- Vomiting
- Xerostomia
More Frequent
Severe
Less Severe
- Chest pain
- Tremor
- Acute abdominal pain
- Cramps
- Dyspnea
- Myalgias
- Nausea
- Oropharyngeal candidiasis
- Urinary tract infection
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Anaphylaxis
- Angina
- Angioedema
- Asthma exacerbation
- Atrial fibrillation
- Cardiac arrhythmia
- Cataracts
- Glaucoma
- Hyperglycemia
- Hypersensitivity drug reaction
- Hypertension
- Hypokalemia
- Hypotension
- Hypothalamic-pituitary insufficiency
- Immunosuppression
- Infection
- Malaise
- Metabolic acidosis
- Ocular hypertension
- Osteopenia
- Paradoxical bronchospasm
- Tachycardia
- Ventricular premature beats
Less Severe
- Anorexia
- Cough
- Dry throat
- Earache
- Epistaxis
- Fatigue
- Flu-like symptoms
- Gastroenteritis
- Nasal passage irritation
- Nervousness
- Palpitations
- Pruritus of skin
- Skin rash
- Symptoms of anxiety
- Urticaria
- Voice change
- Vomiting
Contraindicated
None
Severe Precaution
Mometasone-Formoterol
May cause reduced growth rate and potential HPA-axis suppression. No safety and efficacy in age < 5 yrs.
- 1 Day – 5 Years
- May cause reduced growth rate and potential HPA-axis suppression. No safety and efficacy in age < 5 yrs.
Management or Monitoring Precaution
Mometasone-Formoterol
May reduce growth rate; monitor growth and titrate to lowest effective dose.
- 5 Years – 18 Years
- May reduce growth rate; monitor growth and titrate to lowest effective dose.
Formoterol Fumarate
- Severity Level:
2
- Additional Notes: Insufficient human data available
Mometasone
- Severity Level:
2
- Additional Notes: Acog guidelines rec inhaled corticosteroids for asthma treatment in pregnancy
Contraindicated
None
General | Excretion Potential | Effect on Infant | Notes |
None |
Precaution Exists
Formoterol
Excret in rat studies;Low plasma levels,amt excret unlikely to be clin signif
Unlikely clinically significant amount excreted with top/nasal administration
General | Excretion Potential | Effect on Infant | Notes |
Evaluate use carefully | Unknown | Not known; no or inclusive data | Excret in rat studies;Low plasma levels,amt excret unlikely to be clin signif |
Mometasone
Excret in rat studies;Low plasma levels,amt excret unlikely to be clin signif
Unlikely clinically significant amount excreted with top/nasal administration
General | Excretion Potential | Effect on Infant | Notes |
Evaluate use carefully | Unknown | Not known; no or inclusive data | Unlikely clinically significant amount excreted with top/nasal administration |
No Known Risk
None
General | Excretion Potential | Effect on Infant | Notes |
None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
Maintenance therapy for asthma | |
J45 | Asthma |
J45.2 | Mild intermittent asthma |
J45.20 | Mild intermittent asthma, uncomplicated |
J45.3 | Mild persistent asthma |
J45.30 | Mild persistent asthma, uncomplicated |
J45.4 | Moderate persistent asthma |
J45.40 | Moderate persistent asthma, uncomplicated |
J45.5 | Severe persistent asthma |
J45.50 | Severe persistent asthma, uncomplicated |
J45.9 | Other and unspecified asthma |
J45.90 | Unspecified asthma |
J45.909 | Unspecified asthma, uncomplicated |
0-9 | A-Z |
---|---|
J45 | Asthma |
J45.2 | Mild intermittent asthma |
J45.20 | Mild intermittent asthma, uncomplicated |
J45.3 | Mild persistent asthma |
J45.30 | Mild persistent asthma, uncomplicated |
J45.4 | Moderate persistent asthma |
J45.40 | Moderate persistent asthma, uncomplicated |
J45.5 | Severe persistent asthma |
J45.50 | Severe persistent asthma, uncomplicated |
J45.9 | Other and unspecified asthma |
J45.90 | Unspecified asthma |
J45.909 | Unspecified asthma, uncomplicated |